.Attribute Medication, Published online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) procedure of individuals with HER2+ enhanced breast cancer and energetic or secure brain metastases presented consistent intracranial task and also systemic efficacy of T-DXd.